4D Molecular Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FDMT Nasdaq 2836 www.4dmoleculartherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 4D Molecular Therapeutics, Inc.

4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path - Jan 10th, 2025 1:00 pm
4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway - Jan 10th, 2025 1:00 pm
4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS - Dec 16th, 2024 1:00 pm
4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now - Nov 26th, 2024 11:51 am
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV - Nov 14th, 2024 1:00 pm
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - Nov 13th, 2024 10:20 pm
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - Nov 13th, 2024 9:05 pm
We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely - Oct 30th, 2024 2:26 pm
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? - Oct 14th, 2024 1:59 pm
4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Sep 25th, 2024 1:35 pm
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference - Sep 23rd, 2024 12:00 pm
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate - Sep 19th, 2024 6:34 pm
4D Molecular data ‘bode well’ for eye gene therapy, but shares fall - Sep 19th, 2024 2:30 pm
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day - Sep 18th, 2024 8:05 pm
4DMT Announces Presentations at Upcoming Retina Conferences - Sep 5th, 2024 12:00 pm
4DMT to Participate in the 2024 Cantor Global Healthcare Conference - Sep 3rd, 2024 12:00 pm
4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 - Aug 27th, 2024 12:00 pm
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Aug 23rd, 2024 1:35 pm
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - Aug 12th, 2024 12:00 pm
4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Aug 10th, 2024 2:02 pm